Results 241 to 250 of about 4,391,067 (296)

Why Engage Communities in Biomedical Research?

Bioethics, EarlyView.
ABSTRACT While community engagement in biomedical research is widely lauded, and many reasons to engage communities have been adduced, it is unclear whether all these reasons are equally important, and, if not, which are most important. Here, I argue that, outside of rare circumstances, community engagement should not be understood as seeking ...
Robert Steel
wiley   +1 more source

Epidemiological dynamics and molecular characterization of HIV drug resistance in eastern China from 2020 to 2023. [PDF]

Front Microbiol
Zhu M, Sun Z, Zhang X, Luo W, Wu S, Ye L, Xu K, Chen J.   +7 more
europepmc   +1 more source

The Process Is Not the Point: Moral Uncertainty and Substantive Justice in Health Care Priority Setting

Bioethics, EarlyView.
ABSTRACT Health actors must ration care due to resource constraints. But even when decision makers know the relevant empirical facts about an allocation decision—including how many patients will benefit from a service, which patients will benefit, how much each patient will benefit, and so on—these facts may not provide a clear answer about how to make
Leah Pierson
wiley   +1 more source

Pretreatment HIV Drug Resistance to Integrase Strand Transfer Inhibitors Among Newly Diagnosed HIV Individuals - China, 2018-2023. [PDF]

China CDC Wkly
Hu H, Hao J, Wang D, Liu X, Chen H, Li F, Chen J, Li M, Xin P, Li Y, Li Q, Li H, Li J, Hu J, Song C, Feng Y, Liao L, Ruan Y, Xing H.   +18 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Development of HIV Drug-Resistance Mutations and Antiretroviral Efficacy Among Vietnamese Patients After Failure of 5-Year First-Line Therapy. [PDF]

J Clin Lab Anal
Hung TM, Bang LVN, Van Duyet L.
europepmc   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

HIV-DRIVES: HIV drug resistance identification, variant evaluation, and surveillance pipeline. [PDF]

Access Microbiol
Kanyerezi S, Sserwadda I, Ssemaganda A, Seruyange J, Ayitewala A, Oundo HR, Tenywa W, Kagurusi BA, Tusabe G, Were S, Ssewanyana I, Nabadda S, Namaganda MM, Mboowa G.   +13 more
europepmc   +1 more source

Viral Suppression and HIV Drug Resistance Among Patients on Second-Line Antiretroviral Therapy in Selected Health Facility in Ethiopia. [PDF]

Viruses
Zealiyas K, Gebreegziabxier A, Getaneh Y, Kidane E, Woldesemayat B, Yizengaw A, Gutema G, Adane S, Yimer M, Yilma A, Tadele S, Sasinovich S, Medstrand P, Arimide DA.   +13 more
europepmc   +1 more source

Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China. [PDF]

Pharmaceuticals (Basel)
Zhang J, Sun B, Sheng Z, Ding X, Fan Q, Huang G, Guo Z, Zhong P, Liao L, Xing H, Xia Y, Chai C, Jiang J.   +12 more
europepmc   +1 more source